ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon

JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study

(2009) Vahid Asnafi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor α Homodimers

(2009) Tekla Hornakova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

(2008) E. G. Jeong et al.   CLINICAL CANCER RESEARCH

The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor

(2008) Milica Gakovic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA

IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo

(2008) Caroline Sommereyns et al.   PLoS Pathogens